Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of …

measurable disease
cancer chemotherapy
lung carcinoma
  • 3 views
  • 14 Sep, 2022
  • 78 locations
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of

  • 0 views
  • 10 Jul, 2022
  • 1 location
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.

  • 1 views
  • 06 Jun, 2022
  • 4 locations
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

with a combination of encorafenib and binimetinib in BRAF mutant HCL is more effective than treatment with vemurafenib. Eligibility People ages 18 and older

  • 0 views
  • 27 Jul, 2022
  • 1 location
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

who do not have this mutation, BRAF inhibitors are not a treatment option. We found that in hairy cell leukemia, when BRAF is not mutated, the MEK gene frequently is. Binimetinib is a MEK inhibitor

  • 6 views
  • 25 Jul, 2022
  • 1 location
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C

BRAF
braf v600e mutation
immunomodulators
neutrophil count
immunologic adjuvant
  • 0 views
  • 29 Jul, 2022
  • 17 locations
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

12 weeks with encorafenib + binimetinib followed by combination immunotherapy with nivolumab + ipilimumab improves progression free survival compared to combination immunotherapy nivolumab

measurable disease
metastatic melanoma
ipilimumab
BRAF
ct scan
  • 11 views
  • 16 Feb, 2022
  • 39 locations
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that

measurable disease
metastatic melanoma
pembrolizumab
advanced melanoma
BRAF
  • 0 views
  • 08 Aug, 2022
  • 39 locations
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

This is a multicenter Phase 1b, open-label study to evaluate the pharmacokinetic, safety and efficacy of binimetinib and encorafenib co-administered to adolescent patients with BRAF V600-mutant

metastatic melanoma
cancer
liver metastasis
metastatic cutaneous melanoma
metastasis
  • 24 views
  • 06 Jun, 2022
  • 6 locations
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

braf inhibitor
cancer
BRAF
NRAS
  • 0 views
  • 15 Sep, 2022
  • 20 locations